Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Nonradiographic Axial Spondyloarthritis Topic Center

Featured Article

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
Hannah Musick
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
Jolynn Tumolo
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Hannah Musick
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023

Danielle Sposato

Danielle Sposato
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Jolynn Tumolo
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
Jolynn Tumolo
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
Jolynn Tumolo
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Jolynn Tumolo
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Jolynn Tumolo
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
Jolynn Tumolo
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
News
Earlier Treatment May Improve Outcomes in Patients With Nonradiographic Axial Spondyloarthritis
10/14/2022
Jolynn Tumolo
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs...
10/14/2022
First Report Managed Care

Newsfeed

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
Hannah Musick
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
Jolynn Tumolo
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Hannah Musick
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023

Danielle Sposato

Danielle Sposato
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Jolynn Tumolo
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
Jolynn Tumolo
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
Jolynn Tumolo
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Jolynn Tumolo
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Jolynn Tumolo
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
Jolynn Tumolo
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
News
Exploring the Mechanisms of FDA-Approved siRNA Treatments in Disease Therapy
09/20/2024
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking...
09/20/2024
First Report Managed Care
News
High Mortality and Impairment Rates Among Older Adults in Long-Term Acute Care Hospitals
09/20/2024
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals...
09/20/2024
First Report Managed Care
News
Addressing Stigma is Essential for Increasing PrEP Uptake and Adherence in HIV Prevention Efforts
09/20/2024
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
Addressing stigma associated...
09/20/2024
First Report Managed Care
News
UC Davis Health Unveils Innovative Strategy to Shield Patients With COPD and Asthma From Wildfire Hazards
09/20/2024
As wildfires become an annual threat due to climate change, health systems must proactively adopt air quality-focused population health approaches to protect vulnerable patients with chronic respiratory conditions like COPD and asthma,...
As wildfires become an annual threat due to climate change, health systems must proactively adopt air quality-focused population health approaches to protect vulnerable patients with chronic respiratory conditions like COPD and asthma,...
As wildfires become an annual...
09/20/2024
First Report Managed Care
News
COVID-19 Vaccination Does Not Increase Relapse Risk in Patients With Multiple Sclerosis
09/19/2024
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not...
09/19/2024
First Report Managed Care
News
Obesity Significantly Increases Cancer Risk in Patients With Cardiovascular Disease
09/16/2024
Obesity is associated with an increased cancer risk in patients with cardiovascular disease (CVD), highlighting the need for targeted prevention strategies, according to study results published in the Journal of the American Heart...
Obesity is associated with an increased cancer risk in patients with cardiovascular disease (CVD), highlighting the need for targeted prevention strategies, according to study results published in the Journal of the American Heart...
Obesity is associated with an...
09/16/2024
First Report Managed Care
News
CDC Invests $400 Million to Accelerate HIV Prevention and Surveillance Efforts Nationwide
09/16/2024
The Centers for Disease Control and Prevention (CDC) has awarded $400 million in funding to boost HIV prevention and surveillance efforts across the United States, aiming to accelerate progress in reducing new infections and improving health...
The Centers for Disease Control and Prevention (CDC) has awarded $400 million in funding to boost HIV prevention and surveillance efforts across the United States, aiming to accelerate progress in reducing new infections and improving health...
The Centers for Disease Control...
09/16/2024
First Report Managed Care
News
HHS Unveils Comprehensive Healthcare Reforms to Boost Equity and Quality
09/13/2024
The US Department of Health and Human Services (HHS) has announced updates to Medicare payments and policies to improve healthcare accessibility, equity, and quality for millions of Americans, according to a press release by the HHS.
The US Department of Health and Human Services (HHS) has announced updates to Medicare payments and policies to improve healthcare accessibility, equity, and quality for millions of Americans, according to a press release by the HHS.
The US Department of Health and...
09/13/2024
First Report Managed Care
News
Challenges and Emerging Strategies in Overcoming Resistance in EGFR-Mutant NSCLC
09/10/2024
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results,...
09/10/2024
First Report Managed Care
News
New 4F-PCC Proves Effective in Rapid Reversal of Anticoagulation for Urgent Surgery, Clinical Trial Finds
09/10/2024
An investigational 4-factor prothrombin complex concentrate (4F-PCC) is as effective and safe as an FDA-approved 4F-PCC for rapidly reversing vitamin K antagonist (VKA) anticoagulation in patients requiring urgent surgery, according to a...
An investigational 4-factor prothrombin complex concentrate (4F-PCC) is as effective and safe as an FDA-approved 4F-PCC for rapidly reversing vitamin K antagonist (VKA) anticoagulation in patients requiring urgent surgery, according to a...
An investigational 4-factor...
09/10/2024
First Report Managed Care

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement